{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T08:20:53Z","timestamp":1769934053367,"version":"3.49.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.eururo.2013.08.024","type":"journal-article","created":{"date-parts":[[2013,8,21]],"date-time":"2013-08-21T16:45:20Z","timestamp":1377103520000},"page":"77-78","source":"Crossref","is-referenced-by-count":3,"title":["Factors Related to Side Effects of Intravesical Bacillus Calmette-Gu\u00e9rin: Dose, Maintenance Treatment, and Physicians?"],"prefix":"10.1016","volume":"65","author":[{"given":"Joan","family":"Palou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2013.08.024_bib0005","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0022-5347(17)37707-8","article-title":"A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective?","volume":"146","author":"Pagano","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.08.024_bib0010","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0022-5347(17)37532-8","article-title":"Dose-response of bacillus Calmette-Guerin in the treatment of superficialbladder cancer","volume":"147","author":"Morales","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.08.024_bib0015","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance bacillus Clamette-Guerin for Ta T1 bladder cancer is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial","volume":"44","author":"Van der Meijden","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.08.024_bib0020","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0302-2838(03)00371-3","article-title":"The side effects of bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do no predict its efficacy: results from a European Organization for Research and Treatment of Cancer Genito-Urinary Group phase III trial","volume":"44","author":"Sylvester","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.08.024_bib0025","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomised prospective trial comparing a standard 81mg dose of intravesical bacille Calmette-Gu\u00e9rin with a reduced dose of 27mg in superficial bladder cancer","volume":"89","author":"Martinez-Pineiro","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.08.024_bib0030","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","article-title":"A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27mg) versus very low-dose bacillus Calmette-Guerin (13.5mg) versus mitomycin C","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.08.024_bib0035","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU Cancers Group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.08.024_bib0055","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.08.024_bib0045","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.eursup.2008.08.001","article-title":"Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events","volume":"7","author":"Witjes","year":"2008","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2013.08.024_bib0050","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU guidelines on non\u2013muscle-invasive urothelial carcinoma of the bladder: update 2013","volume":"64","author":"Babjuk","year":"2013","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228381300852X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228381300852X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T15:42:10Z","timestamp":1563723730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228381300852X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S030228381300852X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2013.08.024","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}